- Home
- CLGN vs HKPD Comparison
CLGN vs HKPD Comparison
Compare CLGN & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- HKPD
- Stock Information
- Founded
- CLGN 2004
- HKPD 2016
- Country
- CLGN Israel
- HKPD Hong Kong
- Employees
- CLGN N/A
- HKPD N/A
- Industry
- CLGN Industrial Specialties
- HKPD Other Pharmaceuticals
- Sector
- CLGN Health Care
- HKPD Health Care
- Exchange
- CLGN Nasdaq
- HKPD Nasdaq
- Market Cap
- CLGN 19.1M
- HKPD 20.9M
- IPO Year
- CLGN N/A
- HKPD 2025
- Fundamental
- Price
- CLGN $2.31
- HKPD $1.32
- Analyst Decision
- CLGN Strong Buy
- HKPD
- Analyst Count
- CLGN 2
- HKPD 0
- Target Price
- CLGN $11.50
- HKPD N/A
- AVG Volume (30 Days)
- CLGN 69.8K
- HKPD 161.5K
- Earning Date
- CLGN 08-19-2025
- HKPD 01-01-0001
- Dividend Yield
- CLGN N/A
- HKPD N/A
- EPS Growth
- CLGN N/A
- HKPD N/A
- EPS
- CLGN N/A
- HKPD 0.21
- Revenue
- CLGN $2,472,000.00
- HKPD $20,770,344.00
- Revenue This Year
- CLGN $1,999.42
- HKPD N/A
- Revenue Next Year
- CLGN $69.81
- HKPD N/A
- P/E Ratio
- CLGN N/A
- HKPD $6.04
- Revenue Growth
- CLGN N/A
- HKPD 32.91
- 52 Week Low
- CLGN $1.31
- HKPD $0.81
- 52 Week High
- CLGN $5.45
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- CLGN 65.19
- HKPD N/A
- Support Level
- CLGN $2.16
- HKPD N/A
- Resistance Level
- CLGN $2.28
- HKPD N/A
- Average True Range (ATR)
- CLGN 0.18
- HKPD 0.00
- MACD
- CLGN 0.11
- HKPD 0.00
- Stochastic Oscillator
- CLGN 86.24
- HKPD 0.00
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.